Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emilio Garrido Sanabria

Neurology Naples, FL Medical Doctor

NPI 1235525924 CMS profile 6748938

6101 Pine Ridge Rd, Naples, FL 34119

Open in the dashboard

General payments

$3,621

100 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emilio Garrido Sanabria of Naples, FL is reported in the CMS Open Payments database as having received $3,621 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,481 27
2024 General $981 30
2023 General $832 36
2022 General $219 6
2021 General $109 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emilio Garrido Sanabria
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Emilio Garrido Sanabria were reported at $1,481. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Emilio Garrido Sanabria Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $109 $438 $104–$2,547 $132
2022 $219 $442 $103–$2,388 $149
2023 $832 $464 $119–$2,312 $160
2024 $981 $468 $119–$2,323 $164
2025 $1,481 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $594 14 payments
  2. Neurocrine Biosciences, Inc. $387 18 payments
  3. LivaNova USA, Inc. $344 3 payments
  4. AbbVie, Inc. $338 16 payments
  5. Abbott Laboratories $319 2 payments
  6. Medtronic, Inc. $275 2 payments
  7. Teva Pharmaceuticals USA, Inc. $164 4 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $161 7 payments
  9. Janssen Biotech, Inc. $150 7 payments
  10. Globus Medical, Inc. $148 1 payment
  11. Other $741 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,621 100 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $387 18 payments
  2. Briviact $273 8 payments
  3. BOTOX $269 12 payments
  4. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $218 2 payments
  5. Ongentys $186 8 payments
  6. INFINITY $178 1 payment
  7. PERCEPT PC BRAINSENSE $166 1 payment
  8. SIMPONI ARIA $150 7 payments
  9. STELARA $150 7 payments
  10. SIMPONI $150 7 payments
  11. Other $2,416 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

3,598

Median for Neurology: 833

Drug cost

$403,136

Median for Neurology: $202,670

Branded share of claims

24.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 28 $50,203
Nurtec Odt Rimegepant Sulfate Brand 30 $41,713
Ubrelvy Ubrogepant Brand 25 $38,097
Ajovy Autoinjector Fremanezumab-Vfrm Brand 34 $35,109
Lamictal Xr Lamotrigine Brand 11 $32,996
Aimovig Autoinjector Erenumab-Aooe Brand 24 $28,111
Emgality Pen Galcanezumab-Gnlm Brand 26 $23,823
Rufinamide Generic 23 $20,749
Memantine Hcl Er Memantine Hcl Brand 210 $18,148
Fycompa Perampanel Brand 12 $16,945

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$104,547

Of which drugs: $12,358

Medicare patients

377

Average age 75

Services billed

3,827

194 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 42%
Depression 30%
Atrial fibrillation 27%
Diabetes 24%
Chronic kidney disease 24%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $137
$137 — —
Fintepla
  • UCB, Inc. $118
$118 — —
Briviact
  • UCB, Inc. $103
$103 28 —
BOTOX
  • AbbVie, Inc. $100
$100 — —
VALTOCO
  • Neurelis, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record